Granules India
Granules India is a vertically integrated pharmaceutical manufacturer producing APIs, formulation intermediates, and finished dosages across 10 facilities in India, the US, and Switzerland, serving 300+ pharmaceutical customers in 80+ countries with 69 ANDA approvals.
- Company typePublic
- Founded1991
- HeadquartersMadhapur, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Granules India firmographics
Firmographics- Name
- Granules India
- Legal name
- Granules India Limited
- Website
- https://granulesindia.com
- Company type
- Public
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Granules India is a vertically integrated pharmaceutical manufacturer producing APIs, formulation intermediates, and finished dosages across 10 facilities in India, the US, and Switzerland, serving 300+ pharmaceutical customers in 80+ countries with 69 ANDA approvals.
- Ownership category
- akta.pro rank
Granules India industry classification
Industry- Product category
- Generic Pharmaceuticals Manufacturing
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Granules India is headquartered
LocationHeadquarters
- HQ city
- Madhapur
- HQ country
- India
- HQ region
- Asia
Offices8 records
Markets served
Granules India business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Active Pharmaceutical Ingredients (API): High-volume API manufacturing including paracetamol, metformin, and other essential pharmaceuticals. One of the world's largest paracetamol makers.
- Pharmaceutical Formulation Intermediates (PFI): Compresso product line including directly compressible granules for various molecules used in tablet manufacturing by customers
- Finished Dosages (FDF): Finished pharmaceutical products including tablets, capsules, and other dosage forms sold to pharmaceutical companies and distributors globally
- CDMO Services: Contract development and manufacturing services through acquired Senn Chemicals for peptide therapeutics and other complex molecules
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Granules India product offering
Product offeringCore offering
Granules India is a vertically integrated pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD) for global pharmaceutical companies. It is one of the world's largest paracetamol manufacturers and is expanding into complex generics and peptide-based contract development and manufacturing organization (CDMO) services following its acquisition of Swiss firm Senn Chemicals AG.
Product overview
Granules India is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with over 40 years of proven performance. The company operates across three main product categories: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulations Intermediates (PFI), and Finished Dosages (FD). The company is one of the world's largest paracetamol manufacturers. Recent strategic initiatives include expansion into complex generics and peptide-based contract development and manufacturing (CDMO) services, following the acquisition of Swiss CDMO firm Senn Chemicals AG. Granules serves over 300 customers in more than 80 countries across 10 manufacturing facilities in India, the United States, and Switzerland.
Differentiator
Problem solved
Functional benefit
Brands
- Peptides CDMO Platform: Contract development and manufacturing organization (CDMO) platform for peptide-based therapeutics, enhanced by the acquisition of Swiss firm Senn Chemicals AG
- Complex Generics
Products and services
- Active Pharmaceutical Ingredients (APIs) High-quality active pharmaceutical ingredients manufactured at ICH quality standards, serving as the foundation for finished dosage formulations. Products include APIs across therapeutic categories including analgesics, antihemorrhagics, antiretroviral, antihistamine, antidepressant, antifungal, anticonvulsant, expectorant, muscle relaxant, anti-ulcerative, anticancer, antihypertensive, antibiotic, hypoglycemic, anti-inflammatory agents, and immunomodulatory agents. Sold to global generic pharmaceutical manufacturers.
- Pharmaceutical Formulation Intermediates (PFI) Pre-formulated directly compressible granules serving as intermediate products for tablet manufacturing by pharmaceutical customers. Includes the Compresso product line containing Paracetamol (PAP series in various concentrations like 90%, 96%, 87%), Metformin (MF series), Methocarbamol, Ibuprofen (IBU series), Guaifenesin (GGF series), and other therapeutic compounds.
- Finished Dosages (FD) Ready-to-market finished dosage forms including tablets, capsules, oral solutions, injectables, and extended-release formulations. Products span multiple therapeutic areas such as pain management, diabetes, cardiovascular health, HIV/AIDS, oncology, and neurological disorders. Sold to pharmaceutical companies and distributors globally.
- Acetaminophen/Paracetamol API and Formulations Nonnarcotic analgesic and antipyretic drug. Granules India is one of the world's largest paracetamol manufacturers. Available in multiple forms including suppository, extended-release tablet, and intravenous solution. Available as both API and finished dosage formulations.
- Metformin Hydrochloride API and Formulations Anti-diabetic biguanide medication that lowers glucose production in the liver and increases body sensitivity to insulin. Available as tablet, extended-release tablet, solution, and extended-release suspension. Sold as both API and finished dosage formulations.
- Peptide CDMO Services (via Senn Chemicals AG) Contract development and manufacturing organization (CDMO) services for peptide-based therapeutics, leveraging Senn Chemicals AG's peptide synthesis expertise combined with Granules India's manufacturing scale. Targeted at pharmaceutical companies developing GLP-1, oncology, and other complex peptide therapeutics.
Quantifiable outcome
- Revenue growth of 20% YoY to Rs 53,656 million in FY26
- +3 more outcomes
Companies that use Granules India
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Granules India technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Granules India partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Senn Chemicals AGcoreGranules India acquired Swiss CDMO firm Senn Chemicals AG for CHF 20 million (approximately INR 192.5 crore) in February 2025 to expand into peptide therapeutics and CDMO services. The acquisition leverages Senn's peptide synthesis expertise with Granules' manufacturing capabilities to deliver peptide-based solutions globally.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
Granules India competitors and assessment
Company assessmentDirect peers
- Dr. Reddy's Laboratories: Indian pharmaceutical company with API manufacturing, generic formulations, and biosimilars businesses, with major US presence. Comparable to Granules India in API+finished dosage model, regulated market focus, and complex generics expansion.
- Divi's Laboratories: Indian API manufacturer specializing in complex APIs and custom synthesis for global pharma. Comparable to Granules India on API manufacturing focus, US regulatory dependence, and high-volume production capabilities.
- Laurus Labs: Indian API and formulation manufacturer with strong presence in generic ARV APIs and synthesis capabilities. Highly comparable to Granules India on API manufacturing scale, US generics exposure, and contract development services.
- Ipca Laboratories: Indian pharmaceutical company producing APIs and finished formulations with US market presence. Comparable to Granules India on API manufacturing scale, US generics focus, and manufacturing network in India.
- Natco Pharma: Indian pharmaceutical company with API and finished dosage manufacturing with focus on complex generics including oncology. Comparable to Granules India on complex generics strategy, US ANDAs, and oncology pipeline development.
- Lupin Limited: Indian pharmaceutical company manufacturing APIs and finished generic formulations with strong US presence. Comparable to Granules India in generic dosage forms, US market dependence, and investment in complex generics.
- Aurobindo Pharma: Indian vertically integrated generic pharmaceutical manufacturer producing APIs, formulations, and finished dosages with significant US market exposure. Directly comparable to Granules India in API-to-finished dosage business model and US generics focus.
- Cipla: Indian generic pharmaceutical manufacturer with API and finished dosage capabilities serving regulated and emerging markets. Comparable to Granules in vertical integration, US FDA exposure, and complex generics pipeline expansion.
Broad incumbents
- Sun Pharmaceutical Industries: Largest Indian pharmaceutical company with extensive API, generic, and specialty drug portfolio. Comparable to Granules India on US generics exposure and API manufacturing, but operates at significantly larger scale and broader therapeutic scope.
- Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical company with API manufacturing, formulations, biosimilars, and consumer health businesses. Comparable to Granules India on API manufacturing and US generics focus, with broader product portfolio and biosimilars presence.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Granules India social profiles
Digital presenceGranules India compliance and trust
Trust signalCompliance7 records
Granules India financial estimates
Financial estimateRevenue estimate
Valuation estimate
Granules India leadership team
Management profileNumber of profiles
Profiles4 records
Granules India subsidiaries and ownership
Company hierarchySubsidiaries4 records
Granules India funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Granules India M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Granules India
What does Granules India do?
Granules India is a vertically integrated pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD) for global pharmaceutical companies. It is one of the world's largest paracetamol manufacturers and is expanding into complex generics and peptide-based contract development and manufacturing organization (CDMO) services following its acquisition of Swiss firm Senn Chemicals AG.
Is Granules India a public or private company?
Granules India is a public company. It is classified as public and is currently operating.
When was Granules India founded?
Granules India was founded in 1991. It employs 5,001 to 10,000 people.
Where is Granules India based?
Granules India is headquartered in Madhapur, India, in the Asia region.
How does Granules India make money?
Four revenue lines are on record. Active Pharmaceutical Ingredients (API) is the primary driver. The others are pharmaceutical Formulation Intermediates (PFI), finished Dosages (FDF) and CDMO Services.
Who are Granules India's main competitors?
Direct peers on record are Dr. Reddy's Laboratories, Divi's Laboratories, Laurus Labs, Ipca Laboratories, Natco Pharma, Lupin Limited, Aurobindo Pharma and Cipla. Broad incumbents are Sun Pharmaceutical Industries and Zydus Lifesciences (Cadila Healthcare).
Does Granules India have an API?
No public API is recorded for Granules India.
What industry is Granules India in?
Granules India's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC).